June 25 (Reuters) - CSL Ltd CSL.AX :
* ACQUIRE LATE-STAGE GENE THERAPY CANDIDATE FOR HAEMOPHILIA B FROM UNIQURE
* UNIQURE WILL RECEIVE AN UPFRONT CASH PAYMENT OF US$450 MILLION
* UNIQURE TO COMPLETE PHASE 3 TRIAL AND SCALE UP MANUFACTURE FOR EARLY COMMERCIAL SUPPLY UNDER AGREED PLAN WITH CO
* UNIQURE WIL ALSO GET REGULATORY AND COMMERCIAL SALES MILESTONE PAYMENTS AND ROYALTIES
* UPON CLOSING DEAL, CSL WILL HAVE EXCLUSIVE GLOBAL RIGHT TO COMMERCIALISE AMT-061